Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

LXRX | Lexicon Pharmaceuticals, Inc.

IndexRUT P/E- EPS (ttm)-0.68 Insider Own0.40% Shs Outstand244.92M Perf Week-17.73%
Market Cap271.94M Forward P/E- EPS next Y-0.75 Insider Trans- Shs Float242.47M Perf Month-33.33%
Income-130.70M PEG- EPS next Q-0.21 Inst Own82.30% Short Float / Ratio7.35% / 10.13 Perf Quarter-49.57%
Sales0.40M P/S679.85 EPS this Y-2.10% Inst Trans19.13% Short Interest17.81M Perf Half Y-49.34%
Book/sh0.91 P/B1.27 EPS next Y7.40% ROA-60.40% Target Price5.77 Perf Year-53.04%
Cash/sh1.10 P/C1.06 EPS next 5Y- ROE-97.60% 52W Range1.20 - 3.79 Perf YTD-39.27%
Dividend- P/FCF- EPS past 5Y12.60% ROI- 52W High-69.39% Beta1.21
Dividend %- Quick Ratio10.10 Sales past 5Y-72.70% Gross Margin98.00% 52W Low-3.33% ATR0.10
Employees135 Current Ratio10.10 Sales Q/Q805.70% Oper. Margin- RSI (14)21.54 Volatility9.66% 6.48%
OptionableYes Debt/Eq0.53 EPS Q/Q-33.40% Profit Margin- Rel Volume1.02 Prev Close1.22
ShortableYes LT Debt/Eq0.53 EarningsAug 03 AMC Payout- Avg Volume1.76M Price1.16
Recom2.20 SMA20-27.82% SMA50-35.71% SMA200-48.57% Volume1,793,529 Change-4.53%
Date Action Analyst Rating Change Price Target Change
Mar-07-23Initiated Jefferies Hold $3
Aug-12-22Initiated Piper Sandler Overweight $10
Jan-29-21Upgrade JP Morgan Underweight → Neutral $7
Jan-29-21Downgrade Wedbush Outperform → Neutral $2 → $8
Dec-08-20Upgrade Citigroup Neutral → Buy
Nov-18-20Upgrade Gabelli & Co Hold → Buy
Dec-11-19Downgrade Gabelli & Co Buy → Hold
Nov-08-19Downgrade Citigroup Buy → Neutral $3 → $4
Sep-11-19Upgrade Gabelli & Co Hold → Buy $3
Jul-29-19Downgrade Stifel Buy → Hold $10 → $4
Sep-20-23 12:28PM
Sep-14-23 09:40PM
Sep-07-23 04:30PM
Aug-21-23 09:00AM
09:56AM Loading…
Aug-17-23 09:56AM
Aug-08-23 09:00AM
Aug-04-23 09:12AM
Aug-03-23 05:15PM
Jul-28-23 04:01PM
Jun-30-23 06:52AM
Jun-27-23 06:46AM
08:45PM Loading…
Jun-23-23 08:45PM
Jun-20-23 08:00AM
Jun-15-23 05:00PM
Jun-06-23 04:01PM
Jun-05-23 04:01PM
Jun-04-23 07:00AM
Jun-02-23 09:21AM
Jun-01-23 11:35AM
May-31-23 04:01PM
May-26-23 04:25PM
May-22-23 07:33AM
06:50AM Loading…
May-11-23 06:50AM
May-10-23 04:30PM
May-04-23 10:05AM
May-03-23 11:45AM
May-02-23 04:00PM
Apr-28-23 04:00PM
Apr-22-23 08:15AM
Apr-21-23 09:00AM
Apr-17-23 04:00PM
Mar-06-23 06:00AM
Mar-04-23 12:00PM
Mar-03-23 07:07AM
Mar-02-23 04:00PM
Feb-28-23 05:00PM
Feb-20-23 08:00AM
Feb-01-23 07:56AM
Jan-06-23 04:05PM
Dec-29-22 06:52PM
Dec-22-22 09:22AM
Dec-21-22 04:30PM
Nov-28-22 08:00AM
Nov-15-22 10:00AM
Nov-14-22 04:03PM
Nov-12-22 07:28AM
Nov-11-22 08:58AM
Nov-09-22 04:01PM
Nov-08-22 08:58AM
Nov-06-22 05:29PM
Nov-05-22 10:35AM
Nov-04-22 08:58AM
Oct-31-22 08:59AM
Oct-24-22 08:59AM
Oct-02-22 01:00PM
Sep-20-22 08:59AM
Aug-22-22 04:05PM
Aug-05-22 04:59PM
Aug-02-22 04:01PM
Jul-29-22 08:00AM
Jul-28-22 07:00AM
Jul-27-22 04:01PM
Jun-29-22 04:01PM
Jun-06-22 02:16PM
Jun-01-22 08:00AM
May-31-22 08:00AM
May-11-22 06:35AM
May-05-22 06:00AM
Apr-29-22 08:00AM
Apr-07-22 08:00AM
Apr-04-22 08:00AM
Apr-02-22 12:15PM
Mar-21-22 08:01AM
Mar-18-22 09:57AM
Mar-17-22 04:14PM
Mar-08-22 04:34AM
Mar-04-22 05:10AM
Mar-03-22 06:21PM
Feb-28-22 04:54PM
Feb-25-22 09:03PM
Jan-13-22 09:00AM
Jan-04-22 04:05PM
Jan-03-22 10:46AM
Dec-30-21 04:05PM
Nov-15-21 04:30PM
Nov-14-21 08:35AM
Nov-09-21 08:00AM
Nov-03-21 04:02PM
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WADE JEFFREY LPresident and CFOSep 14Buy1.3810,00013,800264,341Sep 14 05:05 PM
McDermott WendyVP, Human ResourcesAug 04Buy1.846,00011,04028,478Aug 07 04:13 PM
COATS LONNELChief Executive OfficerJun 29Buy2.1610,00021,600814,359Jun 29 04:13 PM
COATS LONNELChief Executive OfficerJun 26Buy2.1810,00021,792804,359Jun 26 04:04 PM
COATS LONNELChief Executive OfficerJun 23Buy2.5010,00024,950794,359Jun 26 04:04 PM
McDermott WendyVP, Human ResourcesJun 23Buy2.4310,00024,30022,478Jun 27 04:22 PM
COATS LONNELChief Executive OfficerJun 22Buy2.3140,00092,400784,359Jun 22 04:01 PM
WADE JEFFREY LPresident and CFOJun 20Buy2.3312,00028,000254,341Jun 20 04:10 PM
Artal International S.C.A.DirectorJun 05Buy2.6027,775,05072,215,13078,634,381Jun 05 04:46 PM
Swain Judith LDirectorMay 21Option Exercise0.009,302040,332May 22 04:07 PM
Palantoni FrankDirectorMay 21Option Exercise0.009,302040,332May 22 04:06 PM
SOBECKI CHRISTOPHER JDirectorMay 21Option Exercise0.009,3020159,023May 22 04:06 PM
NIES ALAN SDirectorMay 21Option Exercise0.009,302041,046May 22 04:05 PM
DEBBANE RAYMONDDirectorMay 21Option Exercise0.009,3020340,847May 22 04:03 PM
LEFKOWITZ ROBERT J MDDirectorMay 21Option Exercise0.009,302040,332May 22 04:04 PM
BARKER SAM LDirectorMay 21Option Exercise0.009,302079,617May 22 04:02 PM
Amouyal PhilippeDirectorMay 21Option Exercise0.009,302040,332May 22 04:01 PM